Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Income from Continuing Operations (2016 - 2025)

Cytosorbents' Income from Continuing Operations history spans 15 years, with the latest figure at 6505000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 6505000.0 for Q4 2025, down 256.52% from a year ago — trailing twelve months through Dec 2025 was 15384358.0 (down 73.96% YoY), and the annual figure for FY2025 was 9207000.0, down 2.35%.
  • Income from Continuing Operations for Q4 2025 was 6505000.0 at Cytosorbents, down from 3170000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 15339024.0 in Q4 2023 to a low of 12200837.0 in Q3 2022.
  • The 5-year median for Income from Continuing Operations is 5383120.5 (2021), against an average of 4446645.45.
  • The sharpest move saw Income from Continuing Operations plummeted 1273.27% in 2021, then soared 2102.15% in 2023.
  • Year by year, Income from Continuing Operations stood at 9307012.0 in 2021, then skyrocketed by 91.77% to 766126.0 in 2022, then soared by 2102.15% to 15339024.0 in 2023, then tumbled by 72.91% to 4156000.0 in 2024, then crashed by 256.52% to 6505000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 6505000.0, 3170000.0, and 4231000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.